Hip surgeons in Japan who are looking for a novel tool for primary and revision total hip arthroplasty now have a new option. Intellijoint Surgical Inc., based in Kitchener, Ontario, has just announced that it has gained market authorization from the Japanese Pharmaceutical and Medical Device Agency (PMDA) for Intellijoint HIP and will begin distribution through an existing partner in Japan.
Intellijoint Surgical Takes on Japanese Market
According to the company, Intellijoint HIP is an “easy-to-use, surgeon-controlled navigation system that provides real-time measurements to optimize implant alignment and positioning during hip replacement surgery.” With a learning curve of five cases or less, says the company, Intellijoint HIP is accurate to within half a millmeter when it comes to offset, to within less than half a millimeter on leg length, and to within less than three degrees.
“Gaining entry into the largest computer-assisted surgical navigation market is a major milestone for our team” says Armen Bakirtzian, co-founder and CEO at Intellijoint. ”We are marching forward on our mission to improve patients’ lives by providing every surgeon with effective, easy-to-use technology.”
Intellijoint HIP, already available in the U.S., Canada and Australia, has been used in 20,000 cases since being launched in 2016.
When OTW asked for background on the process of getting market authorization in Japan, Armen Bakirtzian commented, “The approval process by the PMDA was unlike any other market authorization Intellijoint has received in the past. We are proud to be successful in the process in a way that enables market access with direct control.”
Homing in on the value of this market entry, Bakirtzian added, “The Japanese market is the largest computer-assisted surgical navigation market. In addition, it has established reimbursement for surgical navigation and a high yearly growth rate of arthroplasty procedures.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.